COOPER COMPANIES, INC. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
Albert White III stepped down immediately as President and CEO after 20 years; independent director Walt Rosebrough (STERIS former CEO, 40 years medical device experience) elected Executive Chair to oversee operations pending permanent CEO appointment via Russell Reynolds search. Board refreshment ongoing: Shlomi Nachman (27-year J&J Medical Devices veteran, Vision portfolio leader) joining December 8, 2026; three directors not standing for reelection; redesigned seven-member board announced. Company reaffirms full-year fiscal 2026 guidance.
Why this rating
Forced CEO departure signals operational underperformance; leadership vacuum material for $16.2B company. Experienced interim chair mitigates risk. Guidance reaffirm suggests no immediate crisis, but succession uncertainty is significant headwind.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.